Cargando…

Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation

Oligomeric assemblies of neurotoxic amyloid beta (Abeta) peptides generated by proteolytical processing of the amyloid precursor protein (APP) play a key role in the pathogenesis of Alzheimer’s disease (AD). In recent years, a substantial heterogeneity of Abeta peptides with distinct biophysical and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartlage-Rübsamen, Maike, Bluhm, Alexandra, Piechotta, Anke, Linnert, Miriam, Rahfeld, Jens-Ulrich, Demuth, Hans-Ulrich, Lues, Inge, Kuhn, Peer-Hendrik, Lichtenthaler, Stefan F., Roßner, Steffen, Höfling, Corinna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017857/ https://www.ncbi.nlm.nih.gov/pubmed/29673150 http://dx.doi.org/10.3390/molecules23040924

Ejemplares similares

Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2011)

Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitis
por: Taudte, Nadine, et al.
Publicado: (2021)

Distinct glutaminyl cyclase expression in Edinger–Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Aβ pathology in Alzheimer’s disease
por: Morawski, Markus, et al.
Publicado: (2010)

Endogenous mouse huntingtin is highly abundant in cranial nerve nuclei, co-aggregates to Abeta plaques and is induced in reactive astrocytes in a transgenic mouse model of Alzheimer’s disease
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2019)

A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2021)

Cell Type-Specific Human APP Transgene Expression by Hippocampal Interneurons in the Tg2576 Mouse Model of Alzheimer’s Disease
por: Höfling, Corinna, et al.
Publicado: (2019)

Tetrahydroimidazo[4,5-c]pyridine-Based Inhibitors of Porphyromonas gingivalis Glutaminyl Cyclase
por: Ramsbeck, Daniel, et al.
Publicado: (2021)

The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions
por: Cynis, Holger, et al.
Publicado: (2011)

Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice
por: Hoffmann, Torsten, et al.
Publicado: (2021)

Defined astrocytic expression of human amyloid precursor protein in Tg2576 mouse brain
por: Heiland, Tina, et al.
Publicado: (2018)

Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s disease
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2015)

Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration
por: Becker, Andreas, et al.
Publicado: (2013)

Natural Products from Microalgae with Potential against Alzheimer’s Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors
por: Hielscher-Michael, Stephanie, et al.
Publicado: (2016)

A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects
por: Lues, Inge, et al.
Publicado: (2015)

Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer’s disease-like pathology
por: Gnoth, Kathrin, et al.
Publicado: (2020)

Soluble Variants of Human Recombinant Glutaminyl Cyclase
por: Castaldo, Cristiana, et al.
Publicado: (2013)

In vitro and in silico determination of glutaminyl cyclase inhibitors
por: Tran, Phuong-Thao, et al.
Publicado: (2019)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
por: Bridel, Claire, et al.
Publicado: (2017)

QUINT: Workflow for Quantification and Spatial Analysis of Features in Histological Images From Rodent Brain
por: Yates, Sharon C., et al.
Publicado: (2019)

Immunohistochemical Demonstration of the pGlu79 α-Synuclein Fragment in Alzheimer’s Disease and Its Tg2576 Mouse Model
por: Bluhm, Alexandra, et al.
Publicado: (2022)

Identification of Glutaminyl Cyclase Genes Involved in Pyroglutamate Modification of Fungal Lignocellulolytic Enzymes
por: Wu, Vincent W., et al.
Publicado: (2017)

Upregulation of Glutaminyl Cyclase Contributes to ERS-Induced Apoptosis in PC12 Cells
por: Shang, Qi, et al.
Publicado: (2022)

The Bacteroidetes Q-rule and glutaminyl cyclase activity increase the stability of extracytoplasmic proteins
por: Szczęśniak, Katarzyna, et al.
Publicado: (2023)

Malaria parasite evades mosquito immunity by glutaminyl cyclase–mediated posttranslational protein modification
por: Kolli, Surendra Kumar, et al.
Publicado: (2022)

Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site
por: Booth, Rachell E, et al.
Publicado: (2004)

Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy
por: Gillis, John Stuart
Publicado: (2006)

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy
por: Logtenberg, Meike E. W., et al.
Publicado: (2019)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation
por: Hettmann, Thore, et al.
Publicado: (2020)

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
por: Scheltens, Philip, et al.
Publicado: (2018)

Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
por: Schilling, Stephan, et al.
Publicado: (2018)

Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model
por: Wirths, Oliver, et al.
Publicado: (2009)

Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease
por: Chen, Daoyuan, et al.
Publicado: (2023)

Disturbed Ca(2+) Homeostasis Increases Glutaminyl Cyclase Expression; Connecting Two Early Pathogenic Events in Alzheimer’s Disease In Vitro
por: De Kimpe, Line, et al.
Publicado: (2012)

Chronic treatment with the (iso-)glutaminyl cyclase inhibitor PQ529 is a novel and effective approach for glomerulonephritis in chronic kidney disease
por: Kanemitsu, Naotoshi, et al.
Publicado: (2021)

Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro
por: Köppen, Janett, et al.
Publicado: (2020)

Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review
por: Moreth, Jens, et al.
Publicado: (2013)

Site specific NMR characterization of abeta-40 oligomers cross seeded by abeta-42 oligomers
por: Chang, Han-Wen, et al.
Publicado: (2022)

Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
por: Antonios, Gregory, et al.
Publicado: (2015)

A novel human tau knock-in mouse model reveals interaction of Abeta and human tau under progressing cerebral amyloidosis in 5xFAD mice
por: Barendrecht, Susan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p1d7gtv7emhqfaesec1uo328au